Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$1.02 - $3.23 $11,622 - $36,805
-11,395 Reduced 27.01%
30,789 $39,000
Q4 2023

Jan 12, 2024

BUY
$1.72 - $3.18 $529 - $979
308 Added 0.74%
42,184 $115,000
Q3 2023

Oct 13, 2023

BUY
$2.13 - $5.55 $89,195 - $232,411
41,876 New
41,876 $95,000
Q3 2022

Oct 31, 2022

SELL
$3.02 - $6.12 $4,995 - $10,122
-1,654 Reduced 5.33%
29,389 $180,000
Q2 2022

Jul 29, 2022

BUY
$2.6 - $6.14 $1,677 - $3,960
645 Added 2.12%
31,043 $97,000
Q1 2022

Apr 29, 2022

BUY
$5.08 - $9.81 $47,955 - $92,606
9,440 Added 45.04%
30,398 $173,000
Q4 2021

Feb 07, 2022

BUY
$8.55 - $111.89 $96,495 - $1.26 Million
11,286 Added 116.69%
20,958 $205,000
Q3 2021

Nov 01, 2021

BUY
$76.53 - $110.43 $69,642 - $100,491
910 Added 10.39%
9,672 $1.02 Million
Q2 2021

Aug 12, 2021

SELL
$85.37 - $114.1 $129,677 - $173,317
-1,519 Reduced 14.77%
8,762 $748,000
Q1 2021

May 13, 2021

BUY
$109.73 - $153.66 $672,974 - $942,396
6,133 Added 147.85%
10,281 $1.18 Million
Q4 2020

Feb 04, 2021

SELL
$79.58 - $152.45 $2.86 Million - $5.47 Million
-35,892 Reduced 89.64%
4,148 $581,000
Q3 2020

Nov 09, 2020

BUY
$66.43 - $90.99 $1.22 Million - $1.67 Million
18,367 Added 84.75%
40,040 $3.26 Million
Q2 2020

Jul 20, 2020

BUY
$44.04 - $80.69 $634,616 - $1.16 Million
14,410 Added 198.4%
21,673 $1.56 Million
Q1 2020

Apr 30, 2020

SELL
$44.49 - $93.39 $23,935 - $50,243
-538 Reduced 6.9%
7,263 $323,000
Q4 2019

Jan 28, 2020

BUY
$66.49 - $137.73 $235,108 - $487,013
3,536 Added 82.91%
7,801 $744,000
Q3 2019

Nov 04, 2019

SELL
$31.0 - $89.73 $17,174 - $49,710
-554 Reduced 11.5%
4,265 $335,000
Q2 2019

Jul 29, 2019

BUY
$36.0 - $44.73 $37,440 - $46,519
1,040 Added 27.52%
4,819 $209,000
Q1 2019

Apr 29, 2019

BUY
$33.79 - $51.99 $127,692 - $196,470
3,779 New
3,779 $153,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $81.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.